Sweden's Lumito Q2 loss narrows
Sweden's Lumito Q2 loss narrows
Overview
Sweden medical imaging firm's Q2 sales were flat at SEK 0, with net loss narrowing yr/yr
Company reported first sales in H1 2026, reflecting initial commercialisation progress
Lumito raised SEK 15 mln in rights issue after Q2 to fund commercialisation
Outlook
Lumito says working capital secured through Q1 2027 following recent rights issue
Company says future financing partly depends on outcome of TO10 warrants in Jan 2027
Lumito says focus is on converting SCIZYS interest into recurring business in coming quarters
Result Drivers
PROJECT GRANTS - Other operating income in Q2 was positively impacted by grants from Vinnova and Region Skåne
COST-EFFICIENCY MEASURES - Decreased external and personnel expenses attributed to implemented cost-efficiency measures
STRATEGIC COLLABORATIONS - Company cited deepened collaborations and scientific advances as supporting commercialisation of SCIZYS
Company press release: ID:nMFN8MG4yb
Key Details
Metric | Beat/Miss | Actual | Consensus Estimate |
Q2 Sales |
| SEK 0 |
|
Q2 Adjusted Loss Per Share |
| SEK 2.04 |
|
Q2 Net Loss |
| SEK 10.06 mln |
|
Q2 Adjusted Free Cash Flow |
| -SEK 4.16 mln |
|
Reuters Recommended Reads
Aug 20 - Sweden's Ascelia Pharma Q2 operating loss narrows
Aug 20 - Sweden's Mendus Q2 net loss narrows
Aug 20 - Sweden's SynAct Pharma Q2 net loss narrows on lower expenses
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)